



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 417/12, A61K 31/44, A61P 3/10		A1	(11) International Publication Number: WO 00/64896
			(43) International Publication Date: 2 November 2000 (02.11.00)
(21) International Application Number: PCT/GB00/01520		(Cork) Limited, Curraghbinny, Carrigaline, County Cork (IE).	
(22) International Filing Date: 19 April 2000 (19.04.00)		(74) Agent: RUTTER, Keith; SmithKline Beecham, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).	
(30) Priority Data: 9909473.2 23 April 1999 (23.04.99) GB 9912196.4 25 May 1999 (25.05.99) GB		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). SMITHKLINE BEECHAM (CORK) LIMITED [IE/IE]; Curraghbinny, Carrigaline, County Cork (IE).		Published With international search report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): BLACKLER, Paul, David, James [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). BROWNE, Christine, Marie [IE/IE]; SmithKline Beecham (Cork) Limited, Curraghbinny, Carrigaline, County Cork (IE). COAKLEY, Timothy, G. [IE/IE]; SmithKline Beecham (Cork) Limited, Curraghbinny, Carrigaline, County Cork (IE). GILES, Robert, Gordon [GB/GB]; SmithKline Beecham Pharmaceuticals, Old Powder Mills, Near Leigh, Tonbridge, Kent TN11 9AN (GB). MORRISSEY, Gillian [IE/IE]; SmithKline Beecham			
(54) Title: POLYMORPH OF 5-[4-[2-(N-METHYL-N-(2-PYRIDYL)AMINO) ETHOXY]BENZYL] THIAZOLIDINE-2,4-DIONE, MALEIC ACID SALT			
(57) Abstract A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino) ethoxy]benzyl] thiazolidine-2, 4-dione, maleic acid salt (the "Polymorph") characterised in that it provides: (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm ⁻¹ ; and/or (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm ⁻¹ ; and/or (iii) a solid-state ¹³ C nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

POLYMORPH OF 5-[4-[2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY]BENZYL]THIAZOLIDINE-2,4-DIONE, MALEIC ACID SALT

This invention relates to a novel pharmaceutical, to a process for the
5 preparation of the pharmaceutical and to the use of the pharmaceutical in medicine.

International Patent Application, Publication Number WO94/05659 discloses certain thiazolidinedione derivatives having hypoglycaemic and hypolipidaemic activity including 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (hereinafter also referred to as "Compound (I)").

10 International Patent Applications, Publication Numbers WO99/31093, WO99/31094 and WO99/31095 each disclose distinct hydrates of Compound (I).

It has now been discovered that Compound (I) exists in a novel polymorphic form which is particularly suitable for bulk preparation and handling. The novel form can be prepared by an efficient, economic and reproducible process particularly suited
15 to large-scale preparation.

The novel polymorphic form ('the Polymorph') also has useful pharmaceutical properties and in particular it is indicated to be useful for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

20 Accordingly, the present invention provides a polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt characterised in that it:

- (i) provides an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm^{-1} ; and/or
- 25 (ii) provides a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm^{-1} ; and/or
- (iii) provides a solid-state ^{13}C nuclear magnetic resonance spectrum containing peaks at 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5, 171.0, 178.7 ppm; and/or
- 30 (iv) provides an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms.

In one favoured aspect, the Polymorph provides an infrared spectrum substantially in accordance with Figure I.

In one favoured aspect, the Polymorph provides a Raman spectrum
35 substantially in accordance with Figure II.

In one favoured aspect, the Polymorph provides a solid-state nuclear magnetic resonance spectrum substantially in accordance with Figure III and/or Table I.

In one favoured aspect, the Polymorph provides an X-ray powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or Table II.

The present invention encompasses the Polymorph isolated in pure form or when admixed with other materials, for example the known forms of Compound I (or the "Original Polymorph") or any other material.

Thus in one aspect there is provided the Polymorph in isolated form.

In a further aspect there is provided the Polymorph in pure form.

In yet a further aspect there is provided the Polymorph in crystalline form.

The invention also provides a process for preparing the Polymorph, characterised in that Compound (I) is suspended in acetone, preferably under an inert atmosphere such as nitrogen, and stirred at an elevated temperature, preferably reflux temperature, for an extended period of time, for example 17 hours, after which time the Polymorph is isolated from the reaction mixture.

In an alternative process a solution of Compound (I) in denatured ethanol at an elevated temperature, for example 50°C, is seeded with crystals of the Polymorph then cooled, preferably to a temperature in the range of from 20-25°C, so as to provide the Polymorph, after which time the Polymorph is recovered from the denatured ethanol. The solution of Compound (I) in the denatured ethanol is conveniently prepared by dissolving Compound (I) in the required amount of denatured ethanol at an elevated temperature, for example 60°C.

Typically the Polymorph is recovered from the reaction by filtration and subsequent drying, usually at an elevated temperature, for example 50°C.

In a further aspect, the invention provides a process for converting Polymorph to Compound (I), wherein a solution of Polymorph in a suitable solvent, such as acetone or ethanol, is seeded with Compound (I). Generally, the solution of Polymorph is obtained by dissolving Polymorph at an elevated temperature in the solvent, such as acetone or ethanol.

Compound (I) is prepared according to known procedures, such as those disclosed in WO94/05659. The disclosures of WO94/05659 are incorporated herein by reference.

For the avoidance of doubt the term "Compound (I)" as used herein refers to the form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt as disclosed and characterised in International Patent Application, Publication Number WO94/05659.

When used herein "denatured ethanol" means ethanol containing small amounts of methanol, usually up to 5% v/v of methanol, such as from 0.9% v/v to 5% v/v of methanol, for example ethanol containing 4%v/v of methanol.

When used herein the term 'prophylaxis of conditions associated with diabetes mellitus' includes the treatment of conditions such as insulin resistance, impaired glucose tolerance, hyperinsulinaemia and gestational diabetes.

Diabetes mellitus preferably means Type II diabetes mellitus.

5 Conditions associated with diabetes include hyperglycaemia and insulin resistance and obesity. Further conditions associated with diabetes include hypertension, cardiovascular disease, especially atherosclerosis, certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervosa, and disorders
10 associated with over-eating, such as obesity and anorexia bulimia. Additional conditions associated with diabetes include polycystic ovarian syndrome and steroid induced insulin resistance.

 The complications of conditions associated with diabetes mellitus encompassed herein includes renal disease, especially renal disease associated with
15 the development of Type II diabetes including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.

 As mentioned above the compound of the invention has useful therapeutic properties: The present invention accordingly the Polymorph for use as an active
20 therapeutic substance.

 More particularly, the present invention provides the Polymorph for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

 The Polymorph may be administered per se or, preferably, as a pharmaceutical
25 composition also comprising a pharmaceutically acceptable carrier. The formulation of the Polymorph and dosages thereof are generally as disclosed for Compound (I) in International Patent Application, Publication Number WO94/05659 or WO98/55122.

 Accordingly, the present invention also provides a pharmaceutical composition comprising the Polymorph and a pharmaceutically acceptable carrier
30 therefor.

 The Polymorph is normally administered in unit dosage form.

 The active compound may be administered by any suitable route but usually by the oral or parenteral routes. For such use, the compound will normally be employed in the form of a pharmaceutical composition in association with a
35 pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.

 Compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets,

capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for
5 general use.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.

10 Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

15 Solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily
20 suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats,
25 emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

30 For parenteral administration, fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.

35 Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to
5 facilitate uniform distribution of the active compound.

In addition such compositions may contain further active agents such as anti-hypertensive agents and diuretics.

In addition, the Polymorph may be used in combination with other antidiabetic agents such as insulin secretagogues, for example sulphonylureas, biguanides, such as
10 metformin, alpha glucosidase inhibitors, such as acarbose, beta agonists, and insulin such as those disclosed in WO98/57649, WO98/57634, WO98/57635 or WO98/57636. The other antidiabetic agents, the amounts thereof and methods of administration are as described in the above mentioned publications. The formulation of the Polymorph and dosages thereof in said combinations are generally as disclosed
15 for Compound (I) in the above mentioned publications.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

As used herein the term 'pharmaceutically acceptable' embraces compounds, compositions and ingredients for both human and veterinary use: for example the term
20 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.

The present invention further provides a method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of the Polymorph to a human or
25 non-human mammal in need thereof.

Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.

In the treatment and/or prophylaxis of diabetes mellitus, conditions associated
30 with diabetes mellitus and certain complications thereof the Polymorph may be taken in doses, such as those described above.

Similar dosage regimens are suitable for the treatment and/or prophylaxis of non-human mammals.

In a further aspect the present invention provides the use of the Polymorph for
35 the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

No adverse toxicological effects are indicated in the above mentioned treatments for the compounds of the invention.

The following example illustrates the invention but do not limit it in any way.

Example 1: Preparation of Polymorph

Compound (I) (8.0 g) was suspended in acetone (80 ml) under nitrogen and the resulting slurry was stirred at reflux for 17.5 h. The mixture was then cooled to ambient and stirred for 30 min. The product was isolated by filtration, washed with acetone and dried *in vacuo* at 50°C to give 6.9 g (86%) of the Polymorph.

Example 2: Conversion of Polymorph to Compound (I)

Polymorph (18.0 g) was added to acetone (450 ml) and the resultant mixture was heated at reflux under nitrogen for 30 min. The hot solution was filtered, and the filtered solution was concentrated by distillation at atmospheric pressure (270 ml of acetone was collected). The concentrated solution was then allowed to cool at about 1°C/min and at 50°C the solution was seeded with Compound (I) (0.09 g). Cooling at about 1°C/min was continued. The resulting slurry was stirred for 1 h at ambient temperature, then the solid was isolated by filtration, washed with acetone and dried *in vacuo* at 50°C to give 15.1 g (84%) of Compound (I).

Example 3: Conversion of Polymorph to Compound (I)

A mixture of Polymorph (10.0 g) in denatured ethanol (90 ml) was heated under nitrogen to give a clear solution. The clear solution was stirred at 62°C for 30 min then filtered hot to a vessel preheated to 55°C. The filter was washed with hot denatured ethanol (10 ml). The temperature of the filtrate was adjusted to 60°C before cooling, with stirring, at about 1deg/min. The cooling mixture was seeded at 52°C with Compound (I) (0.4 g) and cooling at 1°C/min with stirring was continued. The resultant slurry was stirred at ambient temperature for 1 h and the solid was isolated by filtration, washed with denatured ethanol and dried *in vacuo* at 50°C to give 8.4 g (84%) of Compound (I).

CHARACTERISING DATA: The following characterising data were generated for the polymorph:

A Infrared

The infrared absorption spectrum of a mineral oil dispersion of the Polymorph was obtained using a Nicolet 710 FT-IR spectrometer at 2 cm⁻¹ resolution. Data were digitised at 1 cm⁻¹ intervals. The spectrum obtained is shown in Figure I. Peak positions are as follows 1763, 1702, 1643, 1623, 1578, 1542, 1515, 1416, 1356, 1334, 1302, 1284, 1261, 1243, 1224, 1201, 1184, 1179, 1147, 1109, 1081, 1055, 1033, 1015, 975, 959, 912, 888, 856, 833, 798, 776, 759, 744, 722, 709, 651, 617, 604, 596, 581, 539, 524 and 505 cm⁻¹.

B Raman

The Raman spectrum of the Polymorph was recorded through a glass vial using a Perkin Elmer 2000R spectrometer at 4 cm⁻¹ resolution and is shown in Figure II (X-axis shows Intensity, Y-axis shows Raman shift cm⁻¹, 1800 - 200 cm⁻¹). Excitation was achieved using a Nd:YAG laser (1064 nm) with a power output of 400 mW. Peak positions are as follows: 1762, 1703, 1613, 1586, 1546, 1469, 1446, 1389, 1333, 1315, 1284, 1264, 1249, 1206, 1181, 1147, 1082, 1035, 1014, 991, 969, 922, 912, 888, 840, 830, 778, 743, 722, 708, 654, 636, 618, 604, 541, 499, 468, 434, 411, 334, 290 and 235 cm⁻¹.

C Solid-State NMR

The 90.56 MHz ¹³C CP-MAS NMR spectrum for the Polymorph is shown in Figure III. Chemical shifts are tabulated in Table 1. Data were recorded at ambient temperature and 10 kHz spinning frequency on a Bruker AMX360 spectrometer, with 1.6 ms cross polarization, and a repetition time of 15 s. Chemical shifts were externally referenced to the carboxylate signal of a glycine test sample at 176.4 ppm relative to tetramethylsilane, and are regarded as accurate to within +/- 0.5 ppm.

Table I.
¹³C Chemical Shifts of the Polymorph.

Chemical Shift (ppm)				
38.5	111.0	130.9	146.5	171.0
50.3	113.6	131.8	152.7	178.7
56.9	119.8	134.7	157.5	
66.0	129.1	138.7	169.5	

D X-Ray Powder Diffraction (XRPD)

The XRPD pattern of the Polymorph is shown below in Figure IV and a summary of the XRPD angles and calculated lattice spacings characteristic of the Polymorph is given in Table II.

Data were acquired on a Bruker D8 Advance X-ray diffractometer with theta/theta geometry configured with a Cu anode, primary and secondary Soller slits, a

secondary monochromator, and scintillation detector. The following acquisition conditions were used:

Tube anode:	Cu
Generator tension:	40 kV
Generator current:	40 mA
Start angle:	2.0 °2 θ
End angle:	35.0 °2 θ
Step size:	0.02 °2 θ
Time per step:	2.5 s

Table II.

X-Ray Powder Diffraction Angles and Calculated Lattice Spacings Characteristic
of the Polymorph.

Diffraction Angle (°2 θ)	Lattice Spacing (Angstroms)
9.9	8.97
12.5	7.07
13.1	6.78
15.1	5.87
15.5	5.72
16.7	5.30
18.9	4.69
20.3	4.38
21.2	4.19
21.7	4.09
22.1	4.02
22.9	3.88
23.4	3.80
23.9	3.72
24.6	3.61
25.2	3.53
25.7	3.46
26.3	3.39
27.1	3.29
27.5	3.25
27.9	3.20
28.7	3.11
29.1	3.07
30.1	2.97
30.5	2.93
30.8	2.91
31.3	2.85
31.7	2.82
32.9	2.72
33.2	2.69
33.8	2.65
34.0	2.64

CLAIMS

1. A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the Polymorph)
5 characterised in that it provides:
 - (i) an infra red spectrum containing peaks at 1763, 912, 856 and 709 cm^{-1} ; and/or
 - (ii) a Raman spectrum containing peaks at 1762, 1284, 912 and 888 cm^{-1} ; and/or
 - (iii) a solid-state ^{13}C nuclear magnetic resonance spectrum containing peaks at
10 111.0, 113.6, 119.8, 129.1, 130.9, 131.8, 134.7, 138.7, 146.5, 152.7, 157.5, 169.5,
171.0, 178.7 ppm; and/or
 - (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice
spacings at 5.87, 5.30, 4.69, 4.09, 3.88, 3.61, 3.53 and 3.46 Angstroms
2. A Polymorph according to claim 1, which provides an infra red spectrum
15 substantially in accordance with Figure I.
3. A Polymorph according to claim 1 or claim 2, which provides provides a
Raman spectrum substantially in accordance with Figure II.
- 20 4. A Polymorph according to any one of claims 1 to 3, which provides provides a
solid-state ^{13}C nuclear magnetic resonance spectrum substantially in accordance with
Figure III and/or Table I.
5. A Polymorph according to any one of claims 1 to 3, which provides an X-ray
25 powder diffraction (XRPD) pattern substantially in accordance with Figure IV and/or
Table II.
6. A Polymorph according to any one of claims 1 to 5, in isolated form.
- 30 7. A Polymorph according to any one of claims 1 to 6, in pure form.
8. A Polymorph according to any one of claims 1 to 7, in crystalline form.
9. A process for preparing a Polymorph according to claim 1, characterised in
35 that either:
 - (a) Compound (I) is suspended in acetone and stirred at an elevated temperature
for an extended period of time; or

(b) Compound (I) in denatured ethanol at an elevated temperature is seeded with crystals of the Polymorph, the reaction mixture is then cooled so as to provide the Polymorph;
after which time the Polymorph is recovered from the denatured ethanol.

5

10. A pharmaceutical composition comprising an effective, non-toxic amount of a Polymorph according to claim 1 and a pharmaceutically acceptable carrier therefor.

11. A Polymorph according to claim 1, for use as an active therapeutic substance.

10

12. A Polymorph according to claim 1, for use in the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

15


13. The use of Polymorph for the manufacture of a medicament for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof.

20

14. A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Polymorph to a human or non-human mammal in need thereof.


1/4

Figure I: Infrared Spectrum of the Polymorph



2/4

Figure II: Raman Spectrum of the Polymorph



Solid-State NMR Spectrum of the Polymorph





Fig IV X-Ray Powder Diffraction Pattern of the Polymorph



INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01520

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/12 A61K31/44 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	WO 99 31093 A (SMITHKLINE BEECHAM PLC) 24 June 1999 (1999-06-24) cited in the application claims 1-17 page 6; example 1	1-14
A	WO 98 55122 A (SMITHKLINE BEECHAM PLC ET AL) 10 December 1998 (1998-12-10) claims 1-21 page 2, line 22 -page 3, line 13	1-14
A	WO 94 05659 A (SMITHKLINE BEECHAM PLC) 17 March 1994 (1994-03-17) cited in the application claims 1-13	1-14
	-/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 July 2000

Date of mailing of the international search report

14/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01520

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HALEBLIAN J ET AL: "PHARMACEUTICAL APPLICATIONS OF POLYMORPHISM" JOURNAL OF PHARMACEUTICAL SCIENCES,US,AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, vol. 58, no. 8, 1 August 1969 (1969-08-01), pages 911-929, XP002020518 ISSN: 0022-3549 page 913, right-hand column, last paragraph -page 914, left-hand column, line 5</p> <p>-----</p>	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01520

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
W0 9931093 A	24-06-1999	AU 2272299 A	05-07-1999
W0 9855122 A	10-12-1998	AU 8215098 A	21-12-1998
		EP 0998284 A	10-05-2000
		NO 995938 A	02-02-2000
W0 9405659 A	17-03-1994	AT 182147 T	15-07-1999
		AU 674880 B	16-01-1997
		AU 4973093 A	29-03-1994
		CA 2143849 A	17-03-1994
		CN 1101911 A,B	26-04-1995
		CN 1183275 A	03-06-1998
		CN 1183413 A,B	03-06-1998
		CN 1183276 A	03-06-1998
		CZ 9500565 A	15-11-1995
		DE 69325658 D	19-08-1999
		DE 69325658 T	30-12-1999
		EP 0658161 A	21-06-1995
		EP 0960883 A	01-12-1999
		ES 2133410 T	16-09-1999
		FI 951004 A	03-03-1995
		FI 982413 A	06-11-1998
		GR 3030794 T	30-11-1999
		HU 72639 A	28-05-1996
		IL 106904 A	30-09-1997
		JP 11147885 A	02-06-1999
		JP 2828777 B	25-11-1998
		JP 8501095 T	06-02-1996
		MX 9305397 A	31-01-1995
		NO 950852 A	03-03-1995
		NO 974646 A	03-03-1995
		NZ 255505 A	22-08-1997
		PL 307812 A	26-06-1995
		RU 2128179 C	27-03-1999
		SG 48302 A	17-04-1998
		SI 9300452 A	30-06-1994
		SK 27795 A	09-08-1995
		US 5741803 A	21-04-1998
		US 5910592 A	08-06-1999
		ZA 9306509 A	16-06-1994